The Translational and Analytical Chemistry Core (TACC) consists of a Chemistry Core Facility and a Nuclear Magnetic Resonance (NMR) Facility. The Chemistry Core began operations in July 2006 and was designated a CCSG developmental shared resource in July 2008. In 2012, the NMR Facility was moved from the Pharmacology &Analytical Facility to the TACC. The mission of the combined core is to assist researchers with the design, synthesis, and analysis of compounds for use in cancer research. The facility is a state-of-the-art organic chemistry lab, offering services ranging from drug design to pre-clinical drug development. The TACC offers two innovative services that other synthesis cores do not. The molecular modeling service allows design of ab inito new chemical agents. Additionally, the TACC offers small molecule X-ray crystallography. The Chemistry Core has experienced average yearly growth of 36% for design and synthesis services (Development, Modeling, and Custom Synthesis) and a decline of 7% for the analytical services (Mass Spec and X-ray). Over the last 5 years, the Chemistry Core has completed 69 projects and synthesized 144 compounds for 35 cancer center members, representing more than 11,200 hours of service. Major equipment for the Chemistry core includes Varian LC-940 HPLC systems, an Agilent Accurate-Mass TOF LC/MS and a Bruker SMART X2S Automated Bench Top X-ray system. The NMR facility is used primarily for structure determination of compounds developed in drug discovery, pharmacology, and diagnostic imaging laboratories. Other uses include macromolecular structure determination and metabolism studies. Usage of the NMR facility increased 147% over the past five years. Instrumentation consists of Bruker 300 MHz DPX, 500 MHz DRX and 600 MHz Avance NMR spectrometers. In the past five years researchers from thirty-two research groups have utilized the laboratory. Peer reviewed investigators account for 87% of utilization of chemistry services and 46% of utilization of the NMR Facility. For the coming grant cycle, TACC requests $232,209 (24%) support from the CCSG. The institution has provided $1,598,359 for purchase of TACC equipment. Publications cited using the TACC have appeared in J Clin Invest and J Natl Cancer Inst. Future plans include the proposed expansion of the facility to incorporate compound screening to provide for early stage hits and access to GMP capabilities to support clinical research studies. The NMR Facility will continue to support the drug discovery and imaging agent research at MD Anderson, and plans to expand into support of metabolomics research.

Public Health Relevance

The Translational and Analytical Chemistry Core provides the capability to synthesize compounds that otherwise would be difficult and costly to obtain through other sources. Novel compounds can also be designed and synthesized to order against a particular biological target. The NMR facility is used extensively for drug discovery and diagnostic imaging research at MD Anderson.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759768
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$266,194
Indirect Cost
$99,893
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Torres, Harrys A; Hosry, Jeff; Mahale, Parag et al. (2018) Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology 67:36-47
Parra, Edwin R; Villalobos, Pamela; Behrens, Carmen et al. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6:48
Yin, Guosheng; Chen, Nan; Lee, J Jack (2018) Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint. Stat Biosci 10:420-438
Nong, Jingying; Gong, Yuhua; Guan, Yanfang et al. (2018) Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 9:3114
Brown, Justin C; Rickels, Michael R; Troxel, Andrea B et al. (2018) Dose-response effects of exercise on insulin among colon cancer survivors. Endocr Relat Cancer 25:11-19
Vakil, Erik; Jimenez, Carlos A; Faiz, Saadia A (2018) Pleural effusions in hematologic malignancies and their management with indwelling pleural catheters. Curr Opin Pulm Med 24:384-391
Yedururi, Sireesha; Chawla, Sumedha; Amini, Behrang et al. (2018) Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. Eur J Radiol 105:49-55
Farinholt, Paige; Park, Minjeong; Guo, Ying et al. (2018) A Comparison of the Accuracy of Clinician Prediction of Survival Versus the Palliative Prognostic Index. J Pain Symptom Manage 55:792-797
Oh, Sang Cheul; Sohn, Bo Hwa; Cheong, Jae-Ho et al. (2018) Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 9:1777
Yang, Yi; Li, Chia-Wei; Chan, Li-Chuan et al. (2018) Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res 28:862-864

Showing the most recent 10 out of 12418 publications